Kubota Pharmaceutical Holdings: change report
Kubota Pharmaceutical Holdings: Notice of obtaining a new patent related to Kubota glasses technology in the United States
Kubota Pharmaceutical Holdings: Notice of relocation and integration of “Kubota Glass” directly managed stores
Kubota Pharmaceutical Holdings: Notice Concerning Issuance of Stock Options (Stock Acquisition Rights)
Kubota Pharmaceutical Holdings: Consolidated Financial Results for the Nine Months Ended September 30, 2024 (under IFRS)
Kubota Pharmaceutical Holdings: Summary of financial results for the 3rd quarter of the fiscal year ending 2024/12 [IFRS] (consolidated)
Kubota Pharmaceutical Holdings: Notice regarding the monthly exercise status of the 33rd Stock Acquisition Rights (with exercise price amendment clause)
Kubota Pharmaceutical Holdings: Notice of progress of specific clinical research using the at-home/remote ophthalmology retinal monitoring device “eyeMO”
Kubota Pharmaceutical Holdings: Change Report
Kubota Pharmaceutical Holdings: Change Report
Kubota Pharmaceutical Holdings: Change Report
Kubota Pharmaceutical Holdings: Notice of obtaining a new patent in the US
Kubota Pharmaceutical Holdings: Notice regarding the monthly exercise status of the 33rd Stock Acquisition Rights (with exercise price amendment clause)
Kubota Pharmaceutical Holdings: Change Report
Kubota Pharmaceutical Holdings: Change report.
Kubota Pharmaceutical Holdings: Notice of obtaining a new patent in the US
Kubota Pharmaceutical Holdings: Notice regarding expiration of the exercise period of the 28th Stock Acquisition Rights (with exercise price amendment clause)
Kubota Pharmaceutical Holdings: Notice regarding completion of payment relating to the issuance of the 33rd Stock Acquisition Rights (with exercise price amendment clause) through third-party allotment
Kubota Pharmaceutical Holdings: Notice regarding the monthly exercise status of the 28th Stock Acquisition Rights (with exercise price amendment clause)
Kubota Pharmaceutical Holdings: Financial results presentation materials for the 2nd quarter of the fiscal year ending 2024/12
No Data
No Data